Remove Cardiology Remove Development Remove Hormones Remove Radiology
article thumbnail

Bayer delivers on medical innovation fueling transformation of pharma business

The Pharma Data

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients.

article thumbnail

A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica

Delveinsight

Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as they announced their partnership deal to develop and market relugolix for prostate cancer and women’s health. . Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist.

Trials 52